HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael Steurer Selected Research

anagrelide (Agrylin)

3/2018Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.
6/2015Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.
1/2014Essential thrombocytemia progressing to Ph+ chronic myeloid leukemia with megakaryoblastic blasts, following anagrelide withdrawal.
2/2009Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.
11/2004Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael Steurer Research Topics

Disease

15Neoplasms (Cancer)
01/2021 - 02/2003
8B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
02/2020 - 06/2004
6Infections
01/2019 - 08/2006
5Hairy Cell Leukemia
01/2019 - 01/2016
5Hemorrhage
01/2018 - 11/2004
5Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
01/2018 - 02/2012
4Lymphoma (Lymphomas)
01/2016 - 04/2008
3Thrombosis (Thrombus)
03/2018 - 04/2003
3Essential Thrombocythemia
06/2015 - 02/2009
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2015 - 04/2003
2Multiple Myeloma
12/2020 - 06/2004
2Disease Progression
12/2019 - 01/2016
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2018 - 01/2013
2Neutropenia
07/2016 - 09/2011
2Thrombocytosis (Thrombocythemia)
02/2009 - 11/2004
1Chromosome Aberrations (Chromosome Abnormalities)
12/2020
1Atrial Fibrillation
02/2020
1Meningitis
12/2019
1Intraocular Lymphoma
01/2019
1Myelitis
01/2019
1Obesity
01/2019
1Residual Neoplasm
10/2018
1Chromothripsis
01/2018
1Hemophilia A (Haemophilia)
03/2017
1Hemoglobinopathies
01/2017
1Pulmonary Hypertension
01/2017
1Brain Neoplasms (Brain Tumor)
01/2016
1Iron Deficiencies
12/2015
1Leukemia
01/2015
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
09/2014
1Sepsis (Septicemia)
09/2014
1Venous Thrombosis (Deep-Vein Thrombosis)
03/2014
1Amyloidosis
03/2014
1Ischemia
03/2014
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2014
1Lymphoid Leukemia
12/2013
1Liver Diseases (Liver Disease)
12/2013
1Weight Gain
12/2013
1Pancreatic Neoplasms (Pancreatic Cancer)
12/2012
1Adenocarcinoma
12/2012
1Neoplasm Metastasis (Metastasis)
12/2012
1Hypereosinophilic Syndrome (Loeffler Endocarditis)
11/2012
1Pruritus (Itching)
11/2012

Drug/Important Bio-Agent (IBA)

6Rituximab (Mabthera)FDA Link
10/2019 - 07/2003
5anagrelide (Agrylin)FDA LinkGeneric
03/2018 - 11/2004
4Inosine Triphosphate (ITP)IBA
01/2018 - 02/2012
3ibrutinibIBA
02/2020 - 01/2017
3romiplostimFDA Link
02/2017 - 01/2015
3Proteins (Proteins, Gene)FDA Link
12/2013 - 04/2008
2Pharmaceutical PreparationsIBA
12/2019 - 01/2016
2Bendamustine HydrochlorideFDA Link
10/2019 - 09/2015
2VemurafenibIBA
01/2019 - 01/2016
2Hemostatics (Antihemorrhagics)IBA
01/2018 - 06/2015
2ofatumumabFDA Link
01/2016 - 12/2013
2IronIBA
12/2015 - 12/2015
2N 30IBA
08/2008 - 04/2008
2T-Cell Antigen Receptors (T-Cell Receptor)IBA
10/2006 - 02/2003
1Immunoglobulins (Immunoglobulin)IBA
12/2020
1Cytarabine (Cytosar-U)FDA LinkGeneric
12/2019
1Delayed-Action PreparationsIBA
12/2019
1ChemokinesIBA
10/2019
1pomalidomideIBA
01/2019
1Immunoglobulin Variable RegionIBA
10/2018
1Biological ProductsIBA
01/2018
1Factor VIII (Coagulation Factor VIII)IBA
03/2017
1recombinant factor VIII N8IBA
03/2017
1Thrombopoietin ReceptorsIBA
01/2017
1CalreticulinIBA
08/2016
1obinutuzumabIBA
01/2016
1InterferonsIBA
01/2016
1fludarabineIBA
01/2016
1Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
01/2016
1CytokinesIBA
12/2015
1Troponin IIBA
06/2015
1pro-brain natriuretic peptide (1-76)IBA
06/2015
1CaspasesIBA
01/2015
1Collagen Type I (Type I Collagen)IBA
01/2015
1Brentuximab VedotinIBA
09/2014
1Retinaldehyde (Retinal)IBA
03/2014
1Anaplastic Lymphoma KinaseIBA
02/2014
1CrizotinibIBA
02/2014
1Complement Factor H (Factor H)IBA
12/2013
1Monoclonal AntibodiesIBA
12/2013
1Phospholipases (Phospholipase)IBA
12/2013
1Propidium (Propidium Iodide)IBA
12/2013
1Triglycerides (Triacylglycerol)IBA
12/2013
1Complement System Proteins (Complement)IBA
12/2013
1Azacitidine (5 Azacytidine)FDA Link
01/2013
1Junctional Adhesion Molecule AIBA
12/2012
1AntigensIBA
12/2012
1Biomarkers (Surrogate Marker)IBA
12/2012
1ParaffinIBA
12/2012
1Glycoproteins (Glycoprotein)IBA
12/2012

Therapy/Procedure

6Therapeutics
01/2021 - 11/2012
2Liver Transplantation
09/2014 - 12/2013
2Drug Therapy (Chemotherapy)
02/2014 - 06/2004
2Stem Cell Transplantation
07/2012 - 07/2003
1Splenectomy
01/2017
1Hematopoietic Stem Cell Transplantation
01/2017
1Phototherapy (Light Therapy)
11/2012